Press Release
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication.
Impressive phase III trial data in AD
Its Priority Review is expected to accelerate its NDA approval
Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas.
Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.
- Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).
- Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.
Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.
Building an integrated AD solution,
strengthening Dermavon’s leadership in dermatology
AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.
Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.
Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health.
More Information About Ruxolitinib Phosphate Cream
Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].
The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).
Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
1. China Insights Consultancy’s industrial report
2. The U.S. FDA approval information can be found on the Incyte official website, as follows:
3. The EMA approval information can be found on the Incyte official website, as follows:
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Kingstown, Saint Vincent and the Grenadines, August 5th, 2026, Chainwire
The former TON executive joins as Director of Strategic Partnerships to form the connections behind ChangeNOW’s next phase.
Former TON executive Martin Masser joins ChangeNOW to build strategic partnerships, ecosystem relationships, and media momentum behind its next phase.
Masser comes with experience across traditional banking, Web2 and Web3, including senior growth and business development roles within the TON space. At ChangeNOW, he will lead strategic relationships with blockchain networks, wallets, fintech companies, payment providers and other infrastructure partners.
His appointment comes as ChangeNOW grows beyond standalone crypto services, transitioning to one connected product where users can buy, store, swap, trade, send, receive and grow digital assets. The industry has already built most of the individual components. What it hasn’t solved is the experience of using them together; clients are still expected to switch between platforms, understand different networks and connect the pieces on their own. ChangeNOW’s super app strategy is designed to move that complexity beneath the product.
“Martin brings a rare mix of commercial relationships, product and media understanding,” said Pauline Shangett, Chief Strategy Officer at ChangeNOW. “He knows what the technology can do, what the business needs and how to make the market pay attention. That is exactly the perspective we need as we build the ChangeNOW super app.”
Masser’s role will focus not on accumulating partnership announcements, but on identifying relationships that can make ChangeNOW’s infrastructure more complete and remove unnecessary steps from the сlient experience.
“The best partnerships create access, adoption and attention. My focus is to build relationships that make the product stronger, simpler and more useful, and then help the market understand why they matter. If you are building wallets, networks, payments, stablecoins, fintech infrastructure, consumer crypto or Web3 products, I want to hear from you,” said Masser.
For consumers, ChangeNOW is combining the core activities of managing crypto within one environment. For businesses, it is developing an integrated set of tools for crypto payments, exchange, stablecoin settlement, digital asset management and Web3 integrations.
As ChangeNOW expands into a crypto super app, its next phase is connecting the right networks, wallets and partners. Masser’s role will be central to building those relationships and turning them into product value, adoption and market momentum.
About ChangeNOW
ChangeNOW.io is a crypto super app built for every crypto move, giving newcomers, professionals, and businesses the tools they need to access Web3 finance in a simple and secure way.
Since 2017, ChangeNOW has grown from a fast, secure, and limitless instant exchange into a trusted platform where storage, swaps, trading, staking, and asset management are covered in one simple experience for millions of clients worldwide.
About Martin Masser
Martin Masser is Director of Strategic Partnerships at ChangeNOW, where he is building partnerships around the company’s expansion into a crypto super app. His career covers traditional banking and capital markets in London and Web3, including his previous role as Head of Growth at TON Foundation. Martin works at the intersection of growth, infrastructure, and partnerships, connecting products and industry players to make crypto services work as one seamless user experience.
Contact
PR Team
CHN Group LLC
pr@changenow.io
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
New York City, New York, August 5th, 2026, FinanceWire
allwhere, the leading IT asset lifecycle management platform, today announced the expansion of its UK operations with the opening of a larger, upgraded depot. The investment increases warehouse capacity, streamlines fulfillment operations, and strengthens allwhere’s ability to support organizations managing employee devices across the United Kingdom.
The upgraded facility represents a significant investment in allwhere’s existing UK infrastructure, enabling the company to deliver faster turnaround times, greater operational efficiency, and additional inventory capacity as demand for global device lifecycle management continues to grow.
“As more organizations build distributed teams, the operational side of IT has become increasingly important,” said Tony Solomon, VP of Global Operations at allwhere. “This investment strengthens the foundation of our UK operations, allowing us to fulfill orders more efficiently, scale alongside our customers, and continue delivering the high level of service they expect from allwhere.”
Built to Support Growing IT Operations
The expanded UK depot enhances every stage of the device lifecycle by improving warehouse operations and increasing fulfillment capacity.
Customers can expect benefits including:
- Faster fulfillment, expedited shipping, and improved turnaround times for deployments and retrievals
- Increased warehouse capacity to support growing inventory needs
- More efficient storage, inventory management, and redeployment workflows
- Standardized operational processes that improve consistency and scalability
- End-to-end lifecycle support managed through a single platform
Whether onboarding a new employee, retrieving equipment from an offboarded team member, storing spare inventory, or preparing devices for redeployment, the upgraded facility enables allwhere to execute these workflows more efficiently while maintaining complete visibility through its platform.
Software and Operations, Unified
Unlike traditional asset management solutions that rely on disconnected software, logistics providers, and warehouses, allwhere combines workflow automation with global operational infrastructure.
Organizations can manage procurement, deployment, inventory, retrievals, storage, repairs, redeployment, and IT asset disposition through a single platform, while allwhere handles the operational execution behind the scenes.
The expanded UK depot further strengthens this model by providing the operational capacity needed to support larger fleets, faster fulfillment, and increasingly complex IT programs.
Continuing to Invest in Global Infrastructure
The UK depot expansion is part of allwhere’s continued investment in its global logistics network. allwhere currently operates full-service depots in the UK, Canada, EU, Mexico, Colombia, Peru, Brazil, Argentina and Uruguay. Later this year, the company plans to further scale its infrastructure into the APAC region, with upcoming depot services in Australia, Japan, Singapore, South Korea, and more.
As organizations continue to scale distributed workforces, allwhere remains focused on expanding the operational infrastructure that powers modern IT teams—combining intelligent software with local logistics expertise to simplify device lifecycle management around the world.
About allwhere
allwhere is a laptop retrieval and IT procurement company that automates the IT asset lifecycle for companies ranging from startups to enterprises. From procurement and deployment to storage, maintenance, and retrieval, allwhere provides the infrastructure businesses need to support a global, distributed workforce.
Contact
Head of Marketing
Brent Singleton
allwhere
info@allwhere.co
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Borderless.xyz Teams Up with Mastercard to Advance Trusted Cross-Border Stablecoin Payment Flows
New York, New York, August 5th, 2026, FinanceWire
Borderless.xyz will explore how Mastercard Crypto Credential can help bring greater trust and confidence to cross-border stablecoin payments.
Borderless.xyz and Mastercard are collaborating on a new pilot to explore how Mastercard Crypto Credential’s standards-based framework can support trusted interactions across cross-border stablecoin payment flows.
Stablecoins are increasingly being used to move value across borders, creating new opportunities for faster and more efficient payments. As adoption grows, participants need trusted ways to understand who they are interacting with and whether counterparties have met appropriate standards and requirements.
Through the pilot, Borderless.xyz and Mastercard will explore how Mastercard Crypto Credential can address that challenge by providing assurance signals that participants can incorporate into their own approval, compliance and risk processes.
Mastercard Crypto Credential helps support trusted and verifiable interactions across digital asset ecosystems. Through common standards and trusted assurance signals, it is designed to help bring more confidence, transparency and certainty to transactions across blockchain networks.
The collaboration pairs Mastercard’s work in building trust and standards for digital asset ecosystems with Borderless.xyz’s network of stablecoin payment providers. Together, the companies are exploring how trusted governance signals can help reduce friction and bring greater confidence to cross-border stablecoin payments as adoption grows.
“One of the biggest friction points for stablecoin payment operators isn’t the payments. It’s that compliance doesn’t scale the same way the network does. Every new provider means starting the verification process over. Correspondent banking solved this decades ago: originating compliance trusted downstream, no re-execution at every counterparty. Mastercard is applying that model to digital asset payments. Borderless.xyz is the network it runs through.” – Kevin Lehtiniitty, CEO and Co-Founder, Borderless.xyz
“Innovation is most powerful when it builds over time. Our relationship with Borderless.xyz began through Start Path and has continued to grow as the digital asset ecosystem has matured,” said Raj Dhamodharan, executive vice president, Blockchain & Digital Assets at Mastercard. “Today, we’re excited to take the next step together, exploring how Mastercard Crypto Credential can help bring greater trust and confidence to stablecoin payment flows across a growing network of participants.”
The pilot brings together several of Borderless.xyz‘s network participants consisting of Infinia, Walapay, and Koywe, many of whom are also alumni of Mastercard Start Path, the company’s startup engagement program. These partners will leverage Mastercard Crypto Credential as some of the first stablecoin payment operators to run on the single-audit compliance model at network scale.
About Borderless.xyz
Borderless.xyz is a global stablecoin orchestration and liquidity network. Its single API connects wallet infrastructure to 15+ licensed stablecoin providers across 100+ countries. It lets businesses enter new markets without new integrations, get failover so payments don’t drop, and make providers compete for your volume on price. Borderless.xyz is SOC 2 Type II certified and headquartered in New York. To learn more, users can visit the website: borderless.xyz.
About Mastercard
Mastercard powers economies and empowers people in 200+ countries and territories worldwide. Together with our customers, we’re building a resilient economy where everyone can prosper. We support a wide range of digital payments choices, making transactions secure, simple, smart and accessible. Our technology and innovation, partnerships and networks combine to deliver a unique set of products and services that help people, businesses and governments realize their greatest potential
Contact
Sarah Cohen
SJC PR
sarah@sjc-pr.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
ChangeNOW Brings Martin Masser Into Its Crypto Super App
allwhere Expands UK Operations with Upgraded Depot
Borderless.xyz Teams Up with Mastercard to Advance Trusted Cross-Border Stablecoin Payment Flows
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release1 week ago
Dr. Angela Zeng Appears on The Breakfast Club to Discuss Traditional Chinese Medicine and Nutrition
-
Press Release1 week ago
TRX Spot and Perpetuals Listing Launches on Backpack, Expanding Access to the TRON Ecosystem
-
Press Release1 week ago
Apex Financial Ltd: Chief Strategic Analyst Christopher James Carter Unveils RWA-AI-Safeguards
-
Press Release5 days ago
The Future of Preventative Healthcare! Dr. Sundardas Annamalay and Dr. Narjit Singh’s Newly Released Book Sheds Light on Cellular Health
-
Press Release5 days ago
ISGroup Publishes Large-Scale Study Showing AI Can Identify Real Software Vulnerabilities
-
Press Release5 days ago
Shattering Industry Norms: Don Kilam Drives Global Expansion Backed by $35.8M Portfolio
-
Press Release5 days ago
D$AVAGE Releases New Hit Single “Chosen One”
-
Press Release4 days ago
TaqFlow Emerges to Overhaul Central Asian Cross-Border Payments